We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure coreplatform@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Edited by
Andrea Fiorillo, University of Campania “L. Vanvitelli”, Naples,Peter Falkai, Ludwig-Maximilians-Universität München,Philip Gorwood, Sainte-Anne Hospital, Paris
Anxiety Disorders (ADs) are the most prevalent mental disorders worldwide and are characterized by a wide variety of psychological and somatic symptoms, which are often misinterpreted as symptoms of a medical condition. ADs carry a large disease burden that impacts negatively on patients’ health-related quality of life and global life satisfaction and disrupts important activities of daily living. In this chapter we analyze the epidemiology and clinical presentation of ADs, highlighting recent innovations and changes in the classification of anxiety disorders in DSM-5 and ICD-11. Main available pharmacological and nonpharmacological therapies for the treatment of ADs, based on the most recent clinical evidence and updated literature, are presented as well. Lastly, we focus the attention on future perspectives about ADs, examining clinical correlations of peripheral biomarkers, neuroimaging, genetics, epigenetics, and microbiota data. These features may be useful to achieve further insight in terms of physiopathology, to support early diagnosis, and to facilitate the prediction of illness susceptibility and treatment response, in order to support clinicians’ practice and to develop personalized treatment strategies.
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.